The Diabetic Foot Journal Details Effectiveness of Antibiotic-eluting Bone Graft Substitute in Management of Bone Infection
BOSTON, Aug. 18, 2022 /PRNewswire-PRWeb/ -- BONESUPPORT, an emerging leader in orthobiologics, announced CERAMENT G is the focus of a new study highlighting the impact of the technology in the management of patients with diabetic foot infection. As the first injectable combination antibiotic bone graft substitute, CERAMENT G can be used in a single-stage procedure to simultaneously support bone remodeling and locally elute Gentamicin (antibiotic) to protect bone healing. The series, recently published in The Diabetic Foot Journal, shows that the use of CERAMENT G which elutes local antibiotic, along with a surgical debridement, can achieve infection clearance close to 90% and limb salvage rates 94%..
"The clinical study published by Vasukutty et al. is powerful validation of our groundbreaking technology for the management of diabetic bone infection, especially in a challenging cohort of patients," said Michael Diefenbeck, EVP of Medical & Clinical Affairs and Chief Medical Officer at BONESUPPORT. "The result of this protocol demonstrating significant limb salvage success, is an improved quality of life for patients and an improved outcome for surgeons. We know this is just the beginning of the impact of our technology for supporting the treatment of bone infections."
Diabetic foot infection is associated with high morbidity and is one of the leading causes of lower limb amputation. It can often be irreversibly debilitating, is susceptible to infection recurrence, and can lead to limb amputations. The authors of the new study presented results of 47 patients from two centers in the UK. Their multidisciplinary protocol involved pre-operative assessment, debridement, culture-specific systemic antibiotics, and local antimicrobial management with an antibiotic eluting biocomposite from BONESUPPORT. Researchers noted that "this is a safe procedure with no local or systemic adverse effects."
BONESUPPORT received market authorization from the U.S. Food and Drug Administration (FDA), for CERAMENT G, for the indication of bone infection (osteomyelitis) in May. For more information about the study, visit Diabetic Foot Journal - and for a deeper dive into BONESUPPORT'S CERAMENT G technology that delivers proven bone remodeling with reliable and local elution of a broad-spectrum antibiotic, visit https://www.bonesupport.com/.
About BONESUPPORT BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit http://www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.
Media Contact
Aimee Eichelberger, Superior PR, 312-952-1528, [email protected]
SOURCE BONESUPPORT
Advertisement
BOSTON, Aug. 18, 2022 /PRNewswire-PRWeb/ -- BONESUPPORT, an emerging leader in orthobiologics, announced CERAMENT G is the focus of a new study highlighting the impact of the technology in the management of patients with diabetic foot infection. As the first injectable combination antibiotic bone graft substitute, CERAMENT G can be used in a single-stage procedure to simultaneously support bone remodeling and locally elute Gentamicin (antibiotic) to protect bone healing. The series, recently published in The Diabetic Foot Journal, shows that the use of CERAMENT G which elutes local antibiotic, along with a surgical debridement, can achieve infection clearance close to 90% and limb salvage rates 94%..
Advertisement
"The clinical study published by Vasukutty et al. is powerful validation of our groundbreaking technology for the management of diabetic bone infection, especially in a challenging cohort of patients," said Michael Diefenbeck, EVP of Medical & Clinical Affairs and Chief Medical Officer at BONESUPPORT. "The result of this protocol demonstrating significant limb salvage success, is an improved quality of life for patients and an improved outcome for surgeons. We know this is just the beginning of the impact of our technology for supporting the treatment of bone infections."
Diabetic foot infection is associated with high morbidity and is one of the leading causes of lower limb amputation. It can often be irreversibly debilitating, is susceptible to infection recurrence, and can lead to limb amputations. The authors of the new study presented results of 47 patients from two centers in the UK. Their multidisciplinary protocol involved pre-operative assessment, debridement, culture-specific systemic antibiotics, and local antimicrobial management with an antibiotic eluting biocomposite from BONESUPPORT. Researchers noted that "this is a safe procedure with no local or systemic adverse effects."
BONESUPPORT received market authorization from the U.S. Food and Drug Administration (FDA), for CERAMENT G, for the indication of bone infection (osteomyelitis) in May. For more information about the study, visit Diabetic Foot Journal - and for a deeper dive into BONESUPPORT'S CERAMENT G technology that delivers proven bone remodeling with reliable and local elution of a broad-spectrum antibiotic, visit https://www.bonesupport.com/.
About BONESUPPORT BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit http://www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.
Media Contact
Aimee Eichelberger, Superior PR, 312-952-1528, [email protected]
SOURCE BONESUPPORT
